KDR and neoplasm: However, apatinib [12], a novel tyrosine kinase inhibitor, highly selectively inhibits vascular endothelial growth factor receptor-2 tyrosine kinase (VEGFR-2) activity and thereby suppresses tumor growth by inhibiting tumor angiogenesis.